Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.66 |
| ▸ | FNTB | P49356 | 16/20 | 0.66 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13529451 | 0.92 | FNTA (0.67) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL29352433 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL8097 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| (S)-Tipifarnib SCHEMBL30436988 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| (S)-Tipifarnib SCHEMBL4429738 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL23633189 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL29371885 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL22772860 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL21544535 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL94807 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700601-B2 | Substituted indazoles of formula 1.0 that are kinase inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | BRCA1, PDK2, PDK1 | FNTA 1642/4885FNTB 2837/4885PGGT1B 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.